Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with atopic dermatitis (AD, syn. atopic eczema) who are treated with systemic immunomodulating medication, a secure, online, de-identified Personal Health Identifier (PHI)-free reporting registry is created.

Visit the website

Clinicians worldwide are encouraged to report ALL cases of COVID-19 in their AD patients treated with systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). The goal is to investigate how factors like the use of systemic immunomodulating drugs, age, gender and comorbidities influence the outcome of COVID-19 in patients with atopic eczema.

SECURE-AD is connected to partner databases to monitor outcome of COVID-19 by other inflammatory diseases (like www.covidibd.org , www.psoprotect.org and www.rheum-covid.org). In the future, they hope to work together with these research groups to realize pooled analyzes.

APH contact person: Angela Bosma: a.l.bosma@amsterdamumc.nl

This is an initiative taken by APH researchers as a result of the COVID-19 outbreak. If you have an initiative to be listed as well, please email us: aph@amsterdamumc.nl.

See all APH COVID-19 initiatives